Preparation of stimuli-responsive mesoporous composites for in-vitro/in-vivo studies against liver cancer
Journal
Journal of Industrial and Engineering Chemistry
Journal Volume
135
Pages
444-456
Date Issued
2024-07-25
Author(s)
DOI
10.1016/j.jiec.2024.01.056
Abstract
In this study, doxorubicin (DOX)-loaded stimulus-responsive mesoporous nanocarriers were prepared and assessed for their controlled release of DOX, along with their in-vitro/in-vivo anticancer efficacy against liver cancer. These nanocarriers contained MCM-41- and Pluronic P123-coated magnetic iron oxide nanoparticles, further loaded with DOX to form MSNs@P123-DOX nanocarriers. Fourier-transform infrared and energy dispersive spectroscopy analyses revealed silica, Fe, COC, Si–O–Si, and carbonyl groups, indicating the successful formation of MSNs@P123-DOX nanocomposites. X-ray diffraction and analysis of X-ray absorption near-edge structure (XANES) and extended X-ray absorption fine-structure (EXAFS) provided insights into the prepared nanocarriers’ Fe3O4 nature. The controlled release studies indicated a pH- (73.3% released DOX in 70 h; pH = 5.4) and thermo-dependent (79.6% released DOX in 70 h; 42 °C) release of DOX. The Weibull kinetics model revealed a high-degree correlation coefficient with R2 values of 0.980–0.991, with the highest R2 obtained at a pH of 5.4 and temperature of 37 °C. In-vivo assessments demonstrated that the tumor sizes post-treatment with PBS, MSNs@P123, PBS-DOX, and MSNs@P123-DOX were measured at 1953.8, 1203.6, 671.0, and 189.4 mm3, respectively. In in-vivo animal studies, MSNs@P123-DOX nanocarriers inhibited liver tumors. The developed MSNs@P123-DOX nanocarriers show significant promise for the targeted delivery of traditional chemotherapeutic drugs, enhancing efficacy substantially.
SDGs
Type
journal article